Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChina Pacific Regulatory News (CPIC)

Share Price Information for China Pacific (CPIC)

Share Price is delayed by 15 minutes
Get Live Data
26.60    0.00 (0.00%)
Bid:
22.60
Ask:
23.60
Spread: 1.00 (4.425%)
Market Cap: $51.18b
CPIC Live PriceLast checked at - London Stock Exchange

Intraday China Pacific Share Chart

  • This share is an international stock.

Notice of 2021 AGM

28 Apr 2022 16:01

RNS Number : 7588J
China Pacific Insurance Grp Co. Ltd
28 April 2022
 

28 April 2022

CHINA PACIFIC INSURANCE (GROUP) CO., LTD.

(A joint stock company incorporated in the People's Republic of China with limited liability)

Notice of the 2021 Annual General Meeting

 

NOTICE IS HEREBY GIVEN that the annual general meeting ("AGM" or "Annual General Meeting") of China Pacific Insurance (Group) Co., Ltd. (the "Company" or "CPIC") will be held at Hyatt Regency Chongming, Lane 799, Lanhai Road, Chenjia Town, Chongming District, Shanghai, on Wednesday, 8 June 2022 at 1:30 p.m., for the purpose of considering, and if thought fit, passing the following resolutions.

 

AS ORDINARY RESOLUTIONS:

 

1. To consider and approve the report of the Board of Directors of the Company for the year 2021

 

2. To consider and approve the report of the Board of Supervisors of the Company for the year 2021

 

3. To consider and approve the annual report of the Company for the year 2021

 

4. To consider and approve the financial statements and report of the Company for the year 2021

 

5. To consider and approve the profit distribution plan of the Company for the year 2021

 

6. To consider and approve the proposal on the appointment of auditors of the Company for the year 2022

 

7. To consider and approve the proposal on adoption of PRC ASBEs in preparation of financialstatements for H-share market

 

8. To consider and approve donations of the Company for the year 2022

 

AS SPECIAL RESOLUTIONS:

 

9. As special business, to authorise the Board of Directors of the Company to determine if the Company shall allot, issue and deal with, A Shares and H Shares, separately or concurrently, according to market conditions and the needs of the Company, provided that the respective number of shares shall not exceed 20% of each of the A Shares or H Shares of the Company in issue on the date of the passing of this special resolution. However, notwithstanding the granting of the general mandate to the Board of Directors, any issue of new A Shares would require another shareholders' approval at a Shareholders' meeting in accordance with the relevant PRC laws and regulations.

 

(1) Subject to paragraphs (3) and (4) below and pursuant to the Company Law of the People's Republic of China (the "Company Law") and the relevant regulatory stipulations (as amended from time to time) of the places where the shares of the Company are listed, the Board of Directors shall be granted a general and unconditional mandate to exercise all the powers of the Company to allot, issue and deal with new shares during the Relevant Period (as hereinafter defined) and to determine the terms and conditions for the allotment and issue of new shares which include, without limitation, the following terms:

 

(a) the class and number of new shares to be issued;

 

(b) the method of determining the issue price and/or the issue price (including the price range of new Shares);

 

(c) the starting and closing dates for the issue;

 

(d) class and number of the new shares to be issued to existing shareholders; and

 

(e) the making or granting of offers, agreements and options which might require the exercise of such powers.

 

(2) The approval in paragraph (1) shall authorise the Board of Directors during the Relevant Period to make or grant offers, agreements and options which would or might require the exercise of such powers after the end of the Relevant Period.

 

(3) The aggregate nominal amount of the new A Shares and new H Shares allotted, issued and dealt with conditionally or unconditionally (whether pursuant to an option or otherwise) by the Board of Directors pursuant to the approval in paragraph (1), other than the shares issued pursuant to a Rights Issue (as hereinafter defined) or the rights to purchase the shares of the Company under any option scheme or similar arrangement, shall not exceed 20% of each of the A Shares and H Shares of the Company in issue as at the date of passing this resolution.

 

(4) In exercising the powers granted in paragraph (1), the Board of Directors must (a) comply with the Company Law and the relevant regulatory stipulations (as amended from time to time) of the places where the shares of the Company are listed; and (b) obtain approval from China Securities Regulatory Commission and other relevant PRC government departments.

 

(5) For the purpose of this resolution:

 

"Relevant Period" means the period from the date of passing this resolution until the earliest of:

 

(a) the conclusion of the next annual general meeting of the Company;

 

(b) the expiration of the 12-month period following the passing of this resolution; and

 

(c) the revocation or variation of the mandate granted under this resolution by a special resolution of the Company's shareholders in a general meeting.

 

"Rights Issue" means the allotment or issue of shares in the Company or other securities which would or might require shares to be allotted and issued pursuant to an offer made to all the shareholders of the Company (excluding for such purpose any shareholder who is resident in a place where such offer is not permitted under the law of that place) and, where appropriate, the holders of other equity securities of the Company entitled to such offer, pro rata (apart from fractional entitlements) to their existing holdings of shares or such other equity securities.

 

(6) The Board of Directors, subject to the approval of the relevant authorities of the PRC and in accordance with the Company Law, shall be authorised to increase the registered capital of the Company to the required amount upon the exercise of the powers pursuant to paragraph (1) above.

 

(7) The Board of Directors shall be authorised to sign the necessary documents, complete the necessary formalities and take other necessary steps to complete the allotment, issue and listing of new shares, provided that the same do not violate the relevant laws, administrative regulations, and regulatory stipulations (as amended from time to time) of the places where the shares of the Company are listed, and the Articles of Association.

 

(8) Subject to the approval of the relevant PRC authorities, the Board of Directors shall be authorised to make amendments to the Articles of Association as appropriate and necessary after the completion of the allotment and issue of new shares according to the method of the allotment and issue of new shares by the Company, the type and number of new shares to be allotted and issued by the Company, and the actual shareholding structure of the Company at the time of completion of the allotment and issue of new shares, in order to reflect the changes in the share capital structure and the registered capital of the Company pursuant to the exercise of this mandate.

 

To authorise the Board to increase the registered capital of the Company to reflect the number of shares authorized to be issued by the Company pursuant to paragraph 1 of the Special Resolution, subject to the resolution to issue shares under paragraph 1 of the Special Resolution, make such amendments to the Articles of Association as he deems appropriate and necessary to reflect the increase in the registered capital of the Company, and to take any other actions and carry out any formalities required to realize the issuance of shares and the increase of the registered capital of the Company pursuant to paragraph 1 of the Special Resolution.

 

10. To consider and approve the proposed amendments to the Articles of Association of the Company in the manner as set out in the section headed "8. Proposed Amendments to The Articles of Association, The Procedural Rules for Shareholders' General Meetings, The Procedural Rules for the Board of Directors and The Procedural Rules for the Board of Supervisors" in the circular of the Company dated 29 April 2022, to grant an authorization to the chairman or his authorized person to make such revisions to the Articles of Association as he deems necessary and appropriate in accordance with the requirements of regulatory authorities during the Company's approval process for the Articles of Association.

 

11. To consider and approve the proposed amendments to the Procedural Rules for Shareholders' General Meetings in the manner as set out in the section headed "8. Proposed Amendments to The Articles of Association, The Procedural Rules for Shareholders' General Meetings, The Procedural Rules for the Board of Directors and The Procedural Rules for the Board of Supervisors" in the circular of the Company dated 29 April 2022, to grant an authorization to the chairman or his authorized person to make such revisions to the Procedural Rules for Shareholders' General Meetings as he deems necessary and appropriate in accordance with the requirements of regulatory authorities during the Company's approval process for the Procedural Rules for Shareholders' General Meetings.

 

12. To consider and approve the proposed amendments to the Procedural Rules for the Board of Directors in the manner as set out in the section headed "8. Proposed Amendments to The Articles of Association, The Procedural Rules for Shareholders' General Meetings, The Procedural Rules for the Board of Directors and The Procedural Rules for the Board of Supervisors" in the circular of the Company dated 29 April 2022, to grant an authorization to the chairman or his authorized person to make such revisions to the Procedural Rules for the Board of Directors as he deems necessary and appropriate in accordance with the requirements of regulatory authorities during the Company's approval process for the Procedural Rules for the Board of Directors.

 

13. To consider and approve the proposed amendments to the Procedural Rules for the Board of Supervisors in the manner as set out in the section headed "8. Proposed Amendments to The Articles of Association, The Procedural Rules for Shareholders' General Meetings, The Procedural Rules for the Board of Directors and The Procedural Rules for the Board of Supervisors" in the circular of the Company dated 29 April 2022, to grant an authorization to the chairman of the Board of Supervisors or his authorized person to make such revisions to the Procedural Rules for the Board of Supervisors as he deems necessary and appropriate in accordance with the requirements of regulatory authorities during the Company's approval process for the Procedural Rules for the Board of Supervisors.

 

REPORTS TO BE REVIEWED

 

14. In relation to the report on performance of Directors and appraisal results of the Company for the year 2021

 

15. In relation to the report on performance of Supervisors and appraisal results of the Company for the year 2021

 

16. In relation to the report on performance of independent Directors of the Company for the year 2021

 

17. The report on the status of related party transactions and the implementation of management system for related party transactions of the Company for the year 2021.

 

 

For details on above resolutions and reports, please see the Appendices at http://www.rns-pdf.londonstockexchange.com/rns/7588J_1-2022-4-28.pdf

 

 

By Order of the Board of Directors

China Pacific Insurance (Group) Co., Ltd.

KONG Qingwei

Chairman

 

 

About CPIC

CPIC is a joint stock company established under the laws of the People's Republic of China with limited liability.

CPIC's registered office is located at 1 South Zhongshan Road, Huangpu District, Shanghai, the People's Republic of China.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOAPPUMACUPPGCR
Date   Source Headline
8th Jun 202612:30 pmRNSApproval of Director's Appointment Qualification
26th May 202611:05 amRNSAppointment of Vice President
20th May 202610:26 amRNSNotice of the 2025 Annual General Meeting
30th Apr 20269:50 amRNSDirector/PDMR Shareholding
28th Apr 202610:48 amRNSPublication of Summaries of Solvency Reports
28th Apr 202610:36 amRNS2026 First Quarter Report
22nd Apr 202610:35 amRNS2025 Sustainability Report
21st Apr 202611:10 amRNS2026 Q1 Results Presentation
14th Apr 202610:07 amRNSPDMR Shareholding
26th Mar 202612:32 pmRNSPublication of Annual Results Presentation
26th Mar 202612:22 pmRNSPublication of Summaries of Solvency Reports
26th Mar 202612:16 pmRNSCPIC 2025 Annual Report
18th Mar 20269:40 amRNSConvening of 2025 Annual Results Presentation
26th Jan 202611:16 amRNSApproval of Director's Appointment Qualification
19th Jan 20269:35 amRNSAnnouncement relating to Premium Income
23rd Dec 202512:55 pmRNSApproval of AoA and Dissolution of the BOS
23rd Dec 202512:55 pmRNSApproval of AoA and Dissolution of the BOS
16th Dec 20259:17 amRNSAnnouncement relating to Premium Income
9th Dec 202510:10 amRNSRelevant presentations on 2025 investor day
4th Dec 20259:58 amRNSApproval of Director's Appointment Qualification
27th Nov 20259:06 amRNSDirector Shareholding
21st Nov 20259:10 amRNSElection of Employee Director
13th Nov 20259:11 amRNSAnnouncement relating to Premium Income
30th Oct 202511:02 amRNSSummaries of the Quarterly Solvency Reports
30th Oct 20259:54 amRNS2025 Third Quarter Report
21st Oct 202510:41 amRNS2025 Q3 Results Presentation
16th Oct 202511:36 amRNSAnnouncement relating to Premium Income
19th Sep 20257:00 amRNSPublication of Offering Circular of Bonds
18th Sep 202510:51 amRNSAnnouncement relating to Premium Income
18th Sep 202510:43 amRNSCompletion of the Issue of Convertible Bonds
18th Sep 202510:40 amRNSNotice of Listing of Convertible Bonds
11th Sep 20257:00 amRNSProposed issue of Bonds under General Mandate
10th Sep 202512:24 pmRNSProposed issue of Convertible Bonds
29th Aug 202512:35 pmRNSAnnouncement on Poll Results for the EGM
28th Aug 20252:24 pmRNSResignation of Supervisor
28th Aug 20251:25 pmRNSPublication of Summaries of Solvency Reports
28th Aug 20251:24 pmRNSPublication of 2025 Interim Results Presentation
28th Aug 20251:17 pmRNS2025 Interim Report
21st Aug 202511:47 amRNSConvening of 2025 Interim Results Presentation
13th Aug 202510:50 amRNSAnnouncement relating to Premium Income
11th Aug 202511:21 amRNSNotice of EGM
30th Jul 20254:01 pmRNSAmendments to the AoA and dissolution of the BOS
15th Jul 202511:23 amRNSAnnouncement relating to Premium Income
24th Jun 202510:23 amRNSResignation of Director of the Board
13th Jun 202510:15 amRNSAnnouncement relating to Premium Income
11th Jun 202512:58 pmRNSPoll Results for the 2024 AGM
6th Jun 202510:48 amRNSApproval of Appointment Qualification
21st May 202511:19 amRNSNotice of the 2024 Annual General Meeting
14th May 202511:30 amRNSAnnouncement relating to Premium Income
12th May 202512:01 pmRNSAnnouncement relating to Change of Committee

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.